Jazz Pharmaceuticals (JAZZ) PT Raised to $175 at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Wall St futures rise as yields, oil dip
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $236.04 --0%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 25 | Down: 15 | New: 31
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 25 | Down: 15 | New: 31
Join SI Premium – FREE
Deutsche Bank raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $175.00 (from $174.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Carvana (CVNA) PT Lowered to $83 at Stephens
- Rocket Cos Inc. (RKT) PT Lowered to $13 at Wells Fargo
- Citi initiates Jazz Pharmaceuticals coverage with Buy rating
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
